Skip to main content
For Healthcare Professionals
Home hero

Novel mechanism of action

JASCAYD® is a preferential PDE4B inhibitor with antifibrotic, immunomodulatory, and vascular effects3,4
Discover how JASCAYD® works

Proven efficacy

JASCAYD® demonstrated a statistically significant reduction in FVC decline5
Explore the data

Well tolerated

JASCAYD® has a favorable tolerability and safety profile with low discontinuation rates6
See safety results

FVC, forced vital capacity.

References

  1. Boehringer Ingelheim. U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. Published December 19, 2025. Accessed March 24, 2026. https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/us-fda-approves-jascayd-nerandomilast-progressive-pulmonary-fibrosis.

  2. Boehringer Ingelheim Pharmaceuticals, Inc. FDA approves OFEV® as first treatment for chronic fibrosing ILDs with a progressive phenotype. Published March 9, 2020. Accessed February 20, 2026. https://www.boehringer-ingelheim.us/press-release/fda-approves-ofev-first-treatment-chronic-fibrosing-ilds-progressive-phenotype.

  3. Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol. 2022;13:838449.

  4. Reininger D, Wolf F, Mayr CH, et al. Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast. Am J Respir Cell Mol Biol. 2025;73(5):700-712.

  5. Maher TM, Assassi S, Azuma A, et al. FIBRONEER-ILD Trial Investigators. Nerandomilast in patients with progressive pulmonary fibrosis. N Engl J Med. 2025;392(22):2203-2214.

  6. Wijsenbeek MS, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Maher TM, Martinez FJ, Oldham JM, Richeldi L, Valenzuela C, Gu H, Ritter I, Stowasser S, Kreuter M. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial. Eur Respir J. Published online March 26, 2026.

MLR ID: PC-AE-102895
Expiry Date: 10/05/2028